Guidelines Updated on Duration of Dual Antiplatelet Tx in CAD

Share this content:
Guidelines Updated on Duration of Dual Antiplatelet Tx in CAD
Guidelines Updated on Duration of Dual Antiplatelet Tx in CAD

THURSDAY, March 31, 2016 (HealthDay News) -- The American College of Cardiology and the American Heart Association Task Force on Clinical Practice Guidelines has updated the recommendations regarding duration of dual antiplatelet therapy (DAPT) for patients with coronary artery disease (CAD). The updated practice guideline was published online March 29 in the Journal of the American College of Cardiology.

Glenn N. Levine, M.D., from the Baylor College of Medicine in Houston, and colleagues issued a focused update to revise existing guideline recommendations on the duration of DAPT in patients with CAD.

According to the authors, after stent implantation, there is no increased risk of stent thrombosis with shorter-duration DAPT, and bleeding complications are fewer; shorter-duration DAPT may be most appropriate for patients treated with newer generation drug-eluting stents. Longer-duration DAPT after stent implantation is associated with an absolute decrease in late stent thrombosis and ischemic complications (about 1 to 2 percent) and an increase in bleeding complications (about 1 percent). Prolonged DAPT seems more favorable for patients with prior myocardial infarction, with a decrease in ischemic events of about 1 to 3 percent and increase in bleeding events of about 1 percent. Prolonged DAPT does not appear to result in increased mortality after stent implantation.

"Treatment with more intensive antiplatelet therapy and treatment for a longer duration of time with antiplatelet medicines in general involves a fundamental trade-off between a decreased risk of future heart attack and an increased risk of bleeding complications," Levine said in a statement.

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »